Illumina, Inc. vs Banco Santander SA — how do they compare? Illumina, Inc. trades at $265 (market cap $39.95B), while Banco Santander SA trades at $13.49 (market cap $192.86B). The key difference: Banco Santander SA is far larger — about 4.8× Illumina, Inc.'s market cap, and Banco Santander SA pays a 2.06% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Banco Santander SA for 55 Days on average.
| ILMN | SAN | |
|---|---|---|
Market Cap | $39.95B | $192.86B |
Volume | 3,169,503 | 10,644,519 |
Sector | Health | Financials |
52-Week High | $293.69 | $15.05 |
52-Week Low | $91.00 | $9.65 |
Typical Hold Time | 83 Days | 55 Days |
Enterprise Value | $41.31B | $360.86B |
Dividend Yield | — | 2.06% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Banco Santander (SAN) trades at $13.66, down 2.5% with bearish technical signals despite strong profitability metrics including 26.25% net margin and 16.07% ROE. The company completed its Webster Financial acquisition in August 2026, expanding U.S. presence while reporting record quarterly profits. Cash flow trends show recent operational challenges with negative $28.13B net cash flow in 2024, though revenue growth remains steady at $60.02B for 2025.
SAN presents a mixed outlook with strong fundamental performance offset by technical weakness. The acquisition-driven growth strategy and technological transformation support long-term value, but negative cash flows and high debt levels ($288.23B long-term debt) pose execution risks. Analyst consensus remains moderately bullish with 64% buy ratings, suggesting potential upside if operational efficiency improves.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →